Vizgen Expands Single-Cell Spatial Transcriptomics Offering with Introduction of MERSCOPE® Ultra Platform and MERFISH 2.0 Chemistry at AACR 2024

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Vizgen, Inc. the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today unveiled the MERSCOPE^® Ultra Platform and MERFISH 2.0 chemistry at the AACR 2024 Annual Meeting. These powerful tools are uniquely suited to supporting basic and translational research and will be commercially available in the second half of the year.

The MERSCOPE Ultra Platform is a powerful new high plex in situ spatial multiomic analysis system. MERSCOPE Ultra features the optimum combined capabilities of imaging area and throughput in a spatial transcriptomics imaging platform. The platform is capable of processing 3 cm² of tissue on a single slide and acquires images at more than double the speed of the MERSCOPE Platform. Engineered for high-performance and optimized for throughput, MERSCOPE Ultra provides researchers with an industry-leading combination of imageable area, speed, and data quality to accelerate discovery and maximize the biology measured from every sample. Further, the system is the only spatial platform to offer two different size flow cells enabling users to adjust reagent consumption based on area imaged.

“The spatial biology market is advancing rapidly, driven by the valuable insights from spatial readouts. Meanwhile, the leap to larger imaging areas will mark a new wave of expansion, broadening the scope and depth of scientific inquiry,” said Stephane Budel, Partner, DeciBio.

Vizgen’s MERFISH 2.0 chemistry leverages improved RNA anchoring and signal enhancement to increase MERFISH’s sensitivity and reproducibility. The optimized chemistry enables broader sample compatibility, improving MERFISH’s performance in archival Formalin-Fixed Paraffin-Embedded (FFPE) samples, and further improving its sensitivity. The company is presenting a poster at AACR showcasing improved sensitivity, reproducibility, and biological accuracy in degraded RNA cancer samples to demonstrate the power of this enhanced chemistry.

“MERSCOPE Ultra elevates our in situ imaging capabilities to unprecedented heights, delivering enhanced throughput and adaptability that supports a range of research to accelerate discovery and biological insights,” said Terry Lo, President and CEO of Vizgen. “MERFISH 2.0 chemistry further improves on MERFISH technology, particularly in FFPE and archival samples. Along with our recent addition of 1000 plex custom panel design capabilities, these solutions provide researchers with a powerful spatial omics solution.”

AACR Poster Presentation Details

Title: Improved spatially resolve single-cell transcriptomic imaging in archival tissues with MERSCOPE
Presenter: George Emanuel, Scientific Co-founder, Senior Director of Technology and Partnerships
Abstract Presentation Number: LB333
Time: Tuesday, April 9, 1:30 – 5:00 pm

About Vizgen^®

Vizgen is dedicated to pioneering the next generation of genomics, providing tools that demonstrate the possibilities of in situ single-cell spatial genomics. The company has established the benchmark in spatial genomics and continues to drive industry innovation, delivering the highest sensitivity as well as excellent specificity and accuracy in cell segmentation. These tools enable researchers to gain new insight into the biological systems that govern human health and disease with spatial context. Vizgen’s MERSCOPE^® Platform enables massively multiplexed, genome-scale nucleic acid imaging with high accuracy and unrivaled detection efficiency at subcellular resolution. MERSCOPE provides transformative insight into a wide range of tissue-scale basic research and translational medicine in oncology, immunology, neuroscience, infectious disease, developmental biology, cell and gene therapy, and is an essential tool for accelerating drug discovery and development. For more information, go to www.vizgen.com. Connect on social media Twitter, LinkedIn and Facebook.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240408988623/en/